Twelve-month MS-related direct cost analysis of relapse outcomes with alemtuzumab versus IFNB-1a in active relapsing-remitting MS (CARE-MS II)

Authors
Category Primary study
JournalJournal of Managed Care and Specialty Pharmacy
Year 2016
This article has no abstract
Epistemonikos ID: 1388ee2e9e399f6692b83a7940de014310105ee1
First added on: Feb 09, 2025